secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2026-05-12T11:04:29+00:00
Accession:  0001628280-26-033859
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned
--------------------------------------------------------------------------------

- Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.
- Cash $165.6M as of Mar 31, 2026; plus $27.3M in April from warrant exercises; runway into 2029.
- Dosed first healthy volunteer in Phase 1 study of OV4071, oral KCC2 direct activator, for psychosis.
- OV329 shows favorable safety/PK up to 9 mg; Phase 2 for focal onset seizures and TSC/infantile spasms planned.
- Raised $60.0M gross from March 2026 PIPE and $53.9M from Series A warrant exercises (Oct 2025 PIPE).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/0001628280-26-033859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/ovid-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer